Start Over

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.

Authors :: Vida Navas EM
Martínez Lorca A
Sancho Gutiérrez A
Sanz Gómez L
Navarro Martínez T
Grande Pulido E
Carrato Mena A
Gajate Borau P
Source :: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Apr 15; Vol. 12, pp. 676973. Date of Electronic Publication: 2021 Apr 15 (Print Publication: 2021).
Publication Year :: 2021
Abstract: Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-treated with <superscript>177</superscript> Lu-DOTATATE and a literature review about salvage treatment with PRRT. We present a 26-year-old man who started with pelvic pain and after a biopsy of a retro-rectal mass observed in a magnetic resonance was diagnosed with an advanced neuroendocrine tumour. After progression to lanreotide, everolimus and sunitinib, treatment with <superscript>177</superscript> Lu-DOTATATE was initiated, achieving an excellent response with a progression free survival (PFS) of 38 months. At the time of progression, re-treatment with <superscript>177</superscript> Lu-DOTATATE was decided, showing a new partial response, which is currently stable after 15 months. The patient had not presented significant treatment-related toxicity. Although there are no randomized phase III trials or a consensus about the number or dose of cycles, there is evidence about the efficacy and low toxicity of salvage treatment with <superscript>177</superscript> Lu-DOTATATE in NETs. Median progression-free survival ranges from 6 to 22 months. Toxicity is mostly hematologic (anemia and neutropenia), 4-7% grade 3/4.<br />Competing Interests: EG has served as advisor and delivered lectures for Pfizer, Bristol-Myers Squibb, Ipsen, Roche, Eisai, Eusa Pharma, MerckSharp&Dohme, Sanofi-Genzyme, Adacap, Novartis, PierreFabre, Lexicon and Celgene. PG has served as advisor and delivered lectures for Pfizer, Bristol-Myers Squibb, Ipsen, Roche, Eisai, Sanofi-Genzyme, Adacap, Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Vida Navas, Martínez Lorca, Sancho Gutiérrez, Sanz Gómez, Navarro Martínez, Grande Pulido, Carrato Mena and Gajate Borau.)